Altimmune reported $480 million in cash as of September 30, 2026, and announced topline data readouts for the RESTORE ALD trial in H2 2027 and PERFORMA in 2029, with a Phase 2 RECLAIM study supporting an AUD program.
Altimmune reported $480 million in cash as of September 30, 2026, and announced topline data readouts for the RESTORE ALD trial in H2 2027 and PERFORMA in 2029, with a Phase 2 RECLAIM study supporting an AUD program.